Skip to main content
. 2018 Oct 16;8:15286. doi: 10.1038/s41598-018-33306-0

Figure 5.

Figure 5

GAS1 mRNA expression in glioblastoma. (A) Results are plotted based on increasing median expression of GAS1 transcripts across 20 major solid tumour types in TCGA (LIHC: Liver hepatocellular carcinoma; KIRP: Kidney Renal Papillary Cell Carcinoma; THCA: thyroid cancer; KIRC: clear cell renal cell carcinoma; COAD: colorectal adenocarcinoma; UCEC: uterine corpus endometrial carcinoma; BLCA: bladder cancer; LUAD: lung adenocarcinoma; STAD: stomach adenocarcinoma; ESCC: esophageal squamous cell carcinoma; CESC: cervical squamous cell carcinoma; PRAD: prostate adenocarcinoma; LUSC: lung squamous cell carcinoma; SKCM: skin cutaneous melanoma; HNSC: head and neck squamous cell carcinoma. PAAD: pancreatic adenocarcinoma; BRCA: breast cancer; GBM: glioblastoma multiforme; OV: ovarian cancer; SARC: sarcoma. (B) Kaplan-Meier curves showing the association between GAS1 mRNA expression and overall survival in TCGA glioblastoma patients. (C) GAS1 mRNA expression in TCGA patients belonging to four glioblastoma subtypes.